Ignite Creation Date:
2024-05-06 @ 7:39 PM
Last Modification Date:
2024-10-26 @ 3:11 PM
Study NCT ID:
NCT06089824
Status:
COMPLETED
Last Update Posted:
2023-10-18
First Post:
2023-10-12
Brief Title:
Drug Utilisation of MysimbaContrave
Sponsor:
Currax Pharmaceuticals
Organization:
Currax Pharmaceuticals
Study Overview
Official Title:
Drug Utilisation and Safety Study of Mysimba in Europe and Contrave in the United States
Status:
COMPLETED
Status Verified Date:
2023-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
DUS
Brief Summary:
This study will assess a retrospective cohort of users of MysimbaContrave with up to 548 days 18 months after initiation with treatment with MysimbaContrave This study will describe MysimbaContrave utilisation and incidence of AESIs for users compliant and non-compliant with the SmPC
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None